Zomedica continues to redefine what is possible in point of care diagnostics with the TRUFORMA biosensor platform ANN ARBOR, MI / ACCESS Newswire / February 6, 2025 / Zomedica Corp. (NYSE American:ZOM ...

The following highlights showcase the most pivotal, innovative research published across multiple therapeutic areas in ...

Its goals were to determine whether the incidence of the primary outcome -- a composite of fatal coronary ... hypertrophy exists, they do not regress LV mass as well as diuretics.

Background Over the past three decades, significant disparities in the global burden of cardiovascular disease (CVD) have ...

Sales increase 13% to $247 Million - Q1 GAAP EPS increases 54% to $0.91 - Q1 Adjusted EPS as defined in prior guidance increases 48% to $0.92 - Q1 Adjusted EPS excluding Acquisition Related ...

For a clinically meaningful change to exist for psoriasis and other chronic, non-life threatening diseases, a treatment must provide an improvement in the patient’s quality of life. In an attempt to ...